

Clinical experience of ceftaroline use in a third-level hospital



A. MAGALLON MARTINEZ, R. HUARTE LACUNZA, A. PINILLA RELLO, L. CAZORLA PODEROSO, M. PÉREZ MORENO, A. LÓPEZ PÉREZ, J. PERALES PASCUAL, M.R. ABAD SAZATORNIL. UNIVERSITARY MIGUEL SERVET HOSPITAL, HOSPITAL PHARMACY, ZARAGOZA, SPAIN

Background and importance: Ceftaroline is approved for the treatment of complicated skin and soft tissue infections(cSSSI), and community-acquired pneumonia(CAP). The most specific aspect of the drug is that it's a b-lactam with activity against methicillinresistant Staphylococcus aureus (MRSA). These charateristics mean that a large part of its use in clinical practice is in in off-label indications.

Aim and objectives: To determine the use of ceftaroline in the clinical practice of a thirdlevel hospital, its effectiveness and safety.


Material and methods: Observational, retrospective



Patients treated with ceftaroline in the hospital from May-2016 to Sept-2020



Variables: age, sex, indication, dose, microorganism, clinical and microbiological cure, and adverse effects.



*MRCNS: methicillin-resistant Coagulase Negative Staphylococcus

38/46 patients Duration of treatment 7 days(1-42) Meticilin resistan microorganism




Posology

- Bacteriemia, endocarditis, CNS infection: 600mg/8h, cSSSI: 600mg/12h.

*In 6 patients it

- Pneumonia: 600 mg/12h in 6/15 and 600 mg/8h in 9/15 patients



Conclusion and relevance: Our results suggest that ceftaroline is effective in severe cases of methicillin-resistant gram-positive infections. In most cases, ceftaroline was used in off-label indications. In these cases, higher dosages are being recommended, which are usually prolonged in time, so it is advisable to evaluate the profile of AE.

Abstract number: 4CPS-255